As millions of children around the world prepare for the winter, parents around the globe are looking for ways to keep their children safe.
It is estimated that at least two million children die each year from malaria, the most deadly of the world’s mosquito-borne diseases.
In recent years, a new vaccine has been developed and is undergoing trials, but experts are concerned about how it might affect people in rural areas.
“The virus is still around in the wild and people are not fully protected from it,” said Dr. Hrithik Roshan, a professor of medicine at Columbia University, who was not involved in the new study.
“We need to do better in urban settings to make sure we are providing effective protection.”
Dr. Roshans findings were published in the Journal of the American Medical Association.
The study, titled “Practical recommendations for protecting children against malaria infection,” surveyed a nationally representative sample of 1,000 parents and caregivers from over 50 countries.
“We did a detailed analysis of the results of the study,” said senior author Dr. Richard Hallett, director of the National Center for Emerging Infectious Diseases at the National Institutes of Health.
Dr. Hallets work is part of a partnership with the United States Centers for Disease Control and Prevention (CDC), the world body that funds research on infectious diseases.
“One of the biggest challenges we face is we are limited in how we can actually do this because of how infectious the disease is,” Dr. Reshan said.
This is because many diseases have a genetic code that allows them to be transmitted through mosquitoes.
“When you have a disease like malaria, you can’t just have it transmitted from one person to another,” he said.
“There is no one person with malaria and you have to protect them.”
Dr Roshany said that the vaccine has not yet been tested on the children of adults.
But, if it does, the vaccine could be a lifesaver.
The vaccine was developed in a partnership between the CDC and a British vaccine company, Wyeth, that had received more than $1.4 billion in research and development.
However, there is a long road ahead before the vaccine can be marketed to the public.
Dr. Michael Fauci, the chairman of the WHO’s panel on vaccine development, said that it is too early to predict the benefits of the vaccine on children.
He said that if the vaccine works, it would not be the first time it has been tested for its safety and effectiveness.
While the vaccine would have some benefits, he added that it would need to be tested in large, randomized clinical trials that would measure its safety.
There are currently a total of 13 vaccines in development.
The vaccines currently being tested are called AZT, the BRAF-1, BRAF and BRAF1, which have been developed in collaboration with Indian pharmaceutical company Novartis and the Swiss drug company AstraZeneca.
Some have already been tested in humans.
They are currently undergoing clinical trials in France, India, the United Kingdom and Brazil, and they are expected to be approved by the end of the year.
A BRAF vaccine is a mixture of BRAF genes and genes from the baboon malaria-fighting gene.
Another vaccine, BRAV, is a combination of the BRAFs BRAF gene and BRAFLP, the gene that codes for the BRAFL proteins found in the blood of humans.
Dr Reshany said it is important that the vaccines are developed and approved in order to ensure that the public has the best chance of receiving the vaccine.
Because of this, he said, the WHO is also working with the United States government on a new set of guidelines to ensure vaccine safety and efficacy for children.
Dr Halleitt said that one of the main concerns he and other experts are having is how well the vaccine is working in children in the developing world.
“In the US, we have seen a lot of resistance to vaccines that have been made for children in developing countries,” he explained.
“We don’t know how well this vaccine will work in the US.
It is really important that we get this vaccine to the US and the rest of the developed world.
We want to make vaccines for children as safe as possible.
Unfortunately, it is a very expensive vaccine, and I think that is why we need to continue working with WHO and other international partners.”